324 related articles for article (PubMed ID: 27143666)
1. Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
Parikh S; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Gao Q; Li F; Were M; Kakuru A; Achan J; Mwebaza N; Aweeka FT
Clin Infect Dis; 2016 Aug; 63(3):414-22. PubMed ID: 27143666
[TBL] [Abstract][Full Text] [Related]
2. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
[TBL] [Abstract][Full Text] [Related]
4. Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
Huang L; Carey V; Lindsey JC; Marzan F; Gingrich D; Graham B; Barlow-Mosha L; Ssemambo PK; Kamthunzi P; Nachman S; Parikh S; Aweeka FT;
PLoS One; 2017; 12(10):e0186589. PubMed ID: 29065172
[TBL] [Abstract][Full Text] [Related]
5. Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Hughes E; Mwebaza N; Huang L; Kajubi R; Nguyen V; Nyunt MM; Orukan F; Mwima MW; Parikh S; Aweeka F
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):140-147. PubMed ID: 31929402
[TBL] [Abstract][Full Text] [Related]
6. Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Kay K; Goodwin J; Ehrlich H; Ou J; Freeman T; Wang K; Li F; Wade M; French J; Huang L; Aweeka F; Mwebaza N; Kajubi R; Riggs M; Ruiz-Garcia A; Parikh S
Clin Pharmacol Ther; 2023 Mar; 113(3):660-669. PubMed ID: 36260349
[TBL] [Abstract][Full Text] [Related]
7. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Byakika-Kibwika P; Lamorde M; Mayito J; Nabukeera L; Namakula R; Mayanja-Kizza H; Katabira E; Ntale M; Pakker N; Ryan M; Hanpithakpong W; Tarning J; Lindegardh N; de Vries PJ; Khoo S; Back D; Merry C
J Antimicrob Chemother; 2012 Sep; 67(9):2213-21. PubMed ID: 22687893
[TBL] [Abstract][Full Text] [Related]
8. Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
Parikh S; Fehintola F; Huang L; Olson A; Adedeji WA; Darin KM; Morse GD; Murphy RL; Taiwo BO; Akinyinka OO; Adewole IF; Aweeka FT; Scarsi KK
Antimicrob Agents Chemother; 2015 Dec; 59(12):7852-6. PubMed ID: 26392500
[TBL] [Abstract][Full Text] [Related]
9. Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
Maganda BA; Minzi OM; Kamuhabwa AA; Ngasala B; Sasi PG
Malar J; 2014 May; 13():205. PubMed ID: 24885714
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.
Tchaparian E; Sambol NC; Arinaitwe E; McCormack SA; Bigira V; Wanzira H; Muhindo M; Creek DJ; Sukumar N; Blessborn D; Tappero JW; Kakuru A; Bergqvist Y; Aweeka FT; Parikh S
J Infect Dis; 2016 Oct; 214(8):1243-51. PubMed ID: 27471317
[TBL] [Abstract][Full Text] [Related]
11. Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
Kredo T; Mauff K; Van der Walt JS; Wiesner L; Maartens G; Cohen K; Smith P; Barnes KI
Antimicrob Agents Chemother; 2011 Dec; 55(12):5616-23. PubMed ID: 21947399
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
German P; Parikh S; Lawrence J; Dorsey G; Rosenthal PJ; Havlir D; Charlebois E; Hanpithakpong W; Lindegardh N; Aweeka FT
J Acquir Immune Defic Syndr; 2009 Aug; 51(4):424-9. PubMed ID: 19506482
[TBL] [Abstract][Full Text] [Related]
13. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
[TBL] [Abstract][Full Text] [Related]
14. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
Huang L; Parikh S; Rosenthal PJ; Lizak P; Marzan F; Dorsey G; Havlir D; Aweeka FT
J Acquir Immune Defic Syndr; 2012 Nov; 61(3):310-6. PubMed ID: 22918158
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.
Whalen ME; Kajubi R; Goodwin J; Orukan F; Colt M; Huang L; Richards K; Wang K; Li F; Mwebaza N; Aweeka FT; Parikh S
Clin Infect Dis; 2023 Feb; 76(3):443-452. PubMed ID: 36130191
[TBL] [Abstract][Full Text] [Related]
16. Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria.
Nyunt MM; Nguyen VK; Kajubi R; Huang L; Ssebuliba J; Kiconco S; Mwima MW; Achan J; Aweeka F; Parikh S; Mwebaza N
Antimicrob Agents Chemother; 2015 Dec; 60(3):1274-82. PubMed ID: 26666942
[TBL] [Abstract][Full Text] [Related]
17. A multi-center, open-label trial to compare the efficacy and pharmacokinetics of Artemether-Lumefantrine in children with severe acute malnutrition versus children without severe acute malnutrition: study protocol for the MAL-NUT study.
Denoeud-Ndam L; Dicko A; Baudin E; Guindo O; Grandesso F; Sagara I; Lasry E; Palma PP; Parra AM; Stepniewska K; Djimde AA; Barnes KI; Doumbo OK; Etard JF
BMC Infect Dis; 2015 Jun; 15():228. PubMed ID: 26068100
[TBL] [Abstract][Full Text] [Related]
18. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications.
Hoglund RM; Byakika-Kibwika P; Lamorde M; Merry C; Ashton M; Hanpithakpong W; Day NP; White NJ; Äbelö A; Tarning J
Br J Clin Pharmacol; 2015 Apr; 79(4):636-49. PubMed ID: 25297720
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
20. The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.
Kredo T; Mauff K; Workman L; Van der Walt JS; Wiesner L; Smith PJ; Maartens G; Cohen K; Barnes KI
BMC Infect Dis; 2016 Jan; 16():30. PubMed ID: 26818566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
